Panagene Inc (046210) - Total Liabilities
Based on the latest financial reports, Panagene Inc (046210) has total liabilities worth ₩24.65 Billion KRW (≈ $16.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Panagene Inc to assess how effectively this company generates cash.
Panagene Inc - Total Liabilities Trend (2005–2024)
This chart illustrates how Panagene Inc's total liabilities have evolved over time, based on quarterly financial data. Check 046210 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Panagene Inc Competitors by Total Liabilities
The table below lists competitors of Panagene Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €53.74 Million |
|
Yuasa Battery (Thailand) Public Company Limited
BK:YUASA
|
Thailand | ฿590.10 Million |
|
Davolink Inc.
KQ:340360
|
Korea | ₩31.74 Billion |
|
2S Metal Public Company Limited
BK:2S
|
Thailand | ฿342.86 Million |
|
Shalimar Paints Limited
NSE:SHALPAINTS
|
India | Rs4.03 Billion |
|
Tirathai Public Company Limited
BK:TRT
|
Thailand | ฿1.86 Billion |
|
Duksung
KO:004830
|
Korea | ₩64.30 Billion |
|
XChange TEC.INC
NASDAQ:XHG
|
USA | $949.73 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Panagene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Panagene Inc (046210) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Panagene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Panagene Inc (2005–2024)
The table below shows the annual total liabilities of Panagene Inc from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩33.57 Billion ≈ $22.75 Million |
+22.77% |
| 2023-12-31 | ₩27.34 Billion ≈ $18.53 Million |
+816.19% |
| 2022-12-31 | ₩2.98 Billion ≈ $2.02 Million |
+44.46% |
| 2021-12-31 | ₩2.07 Billion ≈ $1.40 Million |
-4.43% |
| 2020-12-31 | ₩2.16 Billion ≈ $1.46 Million |
+36.64% |
| 2019-12-31 | ₩1.58 Billion ≈ $1.07 Million |
-79.65% |
| 2018-12-31 | ₩7.77 Billion ≈ $5.27 Million |
-3.51% |
| 2017-12-31 | ₩8.06 Billion ≈ $5.46 Million |
-32.42% |
| 2016-12-31 | ₩11.92 Billion ≈ $8.08 Million |
-28.76% |
| 2015-12-31 | ₩16.73 Billion ≈ $11.34 Million |
+0.92% |
| 2012-12-31 | ₩16.58 Billion ≈ $11.24 Million |
-37.39% |
| 2011-12-31 | ₩26.48 Billion ≈ $17.95 Million |
+22.33% |
| 2010-12-31 | ₩21.65 Billion ≈ $14.67 Million |
+44.59% |
| 2009-12-31 | ₩14.97 Billion ≈ $10.15 Million |
-38.62% |
| 2008-12-31 | ₩24.39 Billion ≈ $16.53 Million |
+47.48% |
| 2007-12-31 | ₩16.54 Billion ≈ $11.21 Million |
-40.36% |
| 2006-12-31 | ₩27.73 Billion ≈ $18.79 Million |
-43.96% |
| 2005-12-31 | ₩49.49 Billion ≈ $33.54 Million |
-- |
About Panagene Inc
Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company a… Read more